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Abstract X gene product of hepatitis B virus (HBV) (HBx)
regulates many transcription factors including nuclear factor
kappa B (NF-UB) and plays a key role in hepatocarcinogenesis.
In this study, we demonstrated that the expression of full HBV
genome and HBx gene similarly stimulated the transcriptional
activity of NF-UB in HuH-7 human hepatoma cells, and that
interferon (IFN)-K as well as dominant negative mutant of IUB
kinase-K e¡ectively inhibited the HBx-mediated NF-UB activa-
tion, but IFN-Q did not. These results suggest that IFN-K may
have a function to block the NF-UB activating pathway trig-
gered by HBx in HBV hepatocytes.
( 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the most preva-
lent malignant diseases worldwide, especially in several areas
of Asia and Africa where hepatitis B virus (HBV) is the major
etiologic factor for HCC. HBV encodes four open reading
frames. Of these, the X gene product of HBV (HBx) is be-
lieved to play a key role in the hepatocarcinogenesis [1,2].
HBx is able to transactivate numerous cellular genes through
activating transcription factors such as AP-1 [3,4], NF-AT [5],
and nuclear factor kappa B (NF-UB) [6^8], which appears to
contribute its oncogenicity.
NF-UB is involved in a number of cellular processes, includ-
ing immune cell activation and development, stress responses,
expression of in£ammatory cytokines, and the control of ap-
optosis [9^13]. Recently, it has been reported that constitutive
activation of NF-UB is detected in HCC tissues but not in
surrounding normal tissues [14], and that NF-UB localization
in HBV-related HCC was closely related to the expression of
HBx [15]. These ¢ndings suggest the possible involvement of
NF-UB in HCC development.
Interferon (IFN)-K plays an essential role in both antiviral
and antitumor host defenses and has been used clinically for
the treatment of viral infections and malignancies [16]. IFN-K
treatment improves the overall clinical outcome in patients
with chronic HBV infection [17,18]. IFN-K also delays or
prevents HCC in patients with HBV-related cirrhosis [19].
In addition, Lai et al. [20] demonstrated a bene¢cial e¡ect
of IFN-K with a 31% response rate in patients with inoperable
HCC caused by chronic HBV or hepatitis C virus infection.
These observations assume that IFN-K may exhibit an anti-
tumor activity in HBV-related HCC through inhibiting the
HBx-mediated cellular responses.
In the present study, we aimed to clarify whether IFN-K
can repress the transacting activity of NF-UB which is stimu-
lated by transfection of either full HBV genome or HBx ex-
pressing vector in human hepatoma cells.
2. Materials and methods
2.1. Cell culture and biological reagents
The HuH-7 human hepatoma cell line was maintained in a chemi-
cally de¢ned medium, IS-RPMI with 5% fetal bovine serum. Re-
combinant human IFN-K2a was provided by Nippon Roche Co. (To-
kyo, Japan) and recombinant human IFN-Q1a was provided by
Shionogi Co. (Osaka, Japan). In some experiments, varying concen-
trations of recombinant human IFN-K2a or recombinant human IFN-
Q1 were added to the cell cultures.
2.2. Plasmids
The full length HBV DNA was cloned into the pGEM11Zf[+] vec-
tor (Promega, Madison, WI, USA) as described previously [21], regis-
tered in GenBank (accession number AB050018), and digested with
Sap1 (New England BioLabs, Beverly, MA, USA) before transfection.
Transfection of the full length linear monometric HBV genome can
initiate a full HBV replication cycle, including production of viral
RNAs, translation of viral proteins and release of virions. [21^23].
The HBx expression vector was generated from adr 125 subtype
HBV DNA (JCRB Gene Bank registry no. VG024). The NcoI^BglII
fragment of HBV DNA containing the entire coding sequence of the
X gene was cloned into the expression vector, pHLApr-1, which con-
tains the human L-actin promoter, in the sense or reverse orientation
[24]. IUB kinase (IKK)K dominant negative form expression vector
was kindly provided by Tularik Inc., South San Francisco, CA,
USA. IUBK dominant negative form expression vector was purchased
from Clontech Laboratories, Inc., Palo Alto, CA, USA.
2.3. Luciferase assay
The pNFUB-Luc (Stratagene, La Jolla, CA, USA) containing four
copies of the binding sequence of NF-UB and ¢re£y luciferase gene
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and pRL-TK-luc (Promega, Madison, WI, USA) containing the her-
pes simplex virus thymidine kinase promoter and expressing renilla
luciferase gene were used in the assay. HuH-7 cells were grown in 24-
well plates, and 0.3^0.5 Wg of pNFUB-Luc and 50 ng of pRL-TK-luc
were transfected with 0.3 Wg of full length HBV DNA or
pGEM11Zf[+] into the cells using FuGENE1-6 (Roche Molecular
Chemicals) according to the manufacturer’s protocol. Similarly, 0.3^
0.5 Wg of pNFUB-Luc and 50 ng of pRL-TK-luc, or 0.3 Wg of pLuc-
MCS (Stratagene) which contains a basic promoter element (TATA
box) but not NF-UB site and 50 ng of pRL-TK-luc were transfected
with 0.3^0.5 Wg of HBx expression vector, reverse-oriented HBx vec-
tor or pHLApr-1 into the cells. In some experiments, dominant neg-
ative IUBK expression vector or dominant negative IKKK expression
vector was cotransfected into the cells. Two days after transfection,
cell lysates were prepared and used for luciferase assay. The luciferase
activities in the cells were determined by a dual-luciferase reporter
assay system and a TD-20/20 luminometer (Promega). Data represent
the ratios of ¢re£y-luc activity derived from pNFUB-Luc or pLuc-
MCS over renilla-luc activity derived from pRL-TK-luc relative to
the control (pGEM11Zf[+] or pHLApr-1).
2.4. Western blot analysis
Immunoblotting with anti-HBx (A⁄nity Bioreagents) or anti-hu-
man L-actin (Sigma, Chemicals Co., St. Louis, MO, USA) was per-
formed as described previously [25]. Cells were lysed by addition of
lysis bu¡er (50 mM Tris, pH 8.0, 150 mM NaCl, 0.02% sodium azide,
0.1% sodium dodecyl sulfate (SDS), 100 Wg/ml PMSF (phenylmetha-
nesulfonyl £uoride), 1 Wg/ml of aprotinin, 1% NP40, 0.5% sodium
deoxycholate) for 10 min at 4‡C, and insoluble material was removed
by centrifugation at 14 000 rpm for 30 min at 4‡C. The same amount
of protein from each lysate (20 Wg/well) was subjected to 15% SDS^
polyacrylamide gel electrophoresis. Proteins were transferred onto ni-
trocellulose membranes which were then blocked for 1.5 h using 5%
non-fat dried milk in phosphate-bu¡ered saline containing 0.1%
Tween 20 (PBS-T), washed with PBS-T and incubated at room tem-
perature for 1 h in the presence of each antibody. The membranes
were washed with PBS-T and incubated with sheep anti-mouse IgG or
donkey anti-rabbit IgG coupled with horseradish peroxidase (Amer-
sham Life Science, Buckinghamshire, UK). The enhanced chemilumi-
nescence system (ECL; Amersham) was used for detection.
3. Results
3.1. The expression of full HBV genome as well as HBx
stimulates transcriptional activity of NF-UB
The e¡ect of full HBV genome expression on the transcrip-
tional activity of NF-UB was determined by transient trans-
fection assay using luciferase reporter plasmid, pNFUB-Luc,
which contains four repeats of the binding sequence of NF-
UB. The full length HBV DNA transfection stimulated the
luciferase activities from NF-UB-Luc at a maximal value 1.8
times higher than that of the control. (Fig. 1A). Similarly, the
transfection of HBx expression vector but not reverse-oriented
HBx vector stimulated the luciferase activities from NF-UB-
Luc at a maximal value 6.9 times higher than that of the
control (Fig. 1B).
Fig. 1. E¡ect of HBV genome expression or HBx on the transcrip-
tional activity of NF-UB in HuH-7 cells. 0.3 Wg of pNFUB-Luc and
50 ng of pRL-TK-luc were cotransfected with 0.3 Wg of
pGEM11Zf[+] control vehicle or 0.3 Wg of full length HBV DNA
into HuH-7 (A). 0.3 Wg of pNFUB-Luc and 50 ng of pRL-TK-luc
were cotransfected with 0.3 Wg of pHLApr-1 control vehicle, 0.3 Wg
of HBx expression vector or 0.3 Wg of reverse-oriented HBx vector,
HBx(R), into HuH-7 (B). Two days after transfection, luciferase ac-
tivity in the cells was analyzed as described in Section 2. Data are
expressed as meanTS.D. of ¢ve separate experiments.
Fig. 2. E¡ect of dominant negative IUBK or IKKK on the HBx-
mediated NF-UB activation. 0.5 Wg of pNFUB-Luc and 50 ng of
pRL-TK-luc were cotransfected with or without 0.5 Wg of HBx ex-
pression vector into HuH-7, together with indicated amounts (Wg)
of dominant negative IUBK expression vector (A) or dominant nega-
tive IKKK expression vector (B). To adjust the amounts of trans-
fected DNA, indicated amounts of pHLApr-1 were also cotrans-
fected. Two days after transfection, luciferase activity in the cells
was analyzed as described in Section 2. Data are expressed as
meanTS.D. of ¢ve separate experiments.
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3.2. HBx-mediated NF-UB activation is reduced by dominant
negative IKKK and IUBK
Since the stimulus-induced degradation of IUBK is essential
for NF-UB activation, we examined the e¡ect of dominant
negative form of IUBK on HBx-mediated NF-UB activation.
As shown in Fig. 2A, The luciferase activity from NF-UB-Luc
which was stimulated by HBx was dose dependently inhibited
by the transfection of IUBK dominant negative expression
vector. It is well known that IKK, a multicomponent protein
complex composed of IKKK, IKKL and IKKQ phosphory-
lates IUB and leads its degradation. Therefore, we examined
whether dominant negative mutant of IKKK inhibit HBx-
mediated NF-UB activation. As shown in Fig. 2B, the lucifer-
ase activity from NF-UB-Luc which was stimulated by HBx
was signi¢cantly inhibited by the transfection of IKKK dom-
inant negative expression vector in a dose-dependent manner.
Taken together, it is possible that NF-UB activation by HBx is
mediated by activation of IKKK and sequential IUBK degra-
dation.
3.3. IFN-K but not IFN-Q e¡ectively inhibits the HBx-mediated
NF-UB activation
Next, we examined the e¡ects of IFN-K on the HBx-medi-
ated NF-UB activation in HuH-7 cells. As shown in Fig. 3C,
the luciferase activity from NF-UB-Luc which was stimulated
by HBx was signi¢cantly inhibited by the addition of IFN-K
Fig. 3. E¡ect of IFN-K on the HBx-mediated NF-UB activation. A: HuH-7 cells were transfected with 0.3 Wg of pHLApr-1 (lanes 1 and 2) or
HBx expression vector (lanes 3 and 4). Twenty-four hours later, the cells were incubated with (lane 2 and 4) or without (lanes 1 and 3) 100
IU/ml of IFN-K for 24 h, then HBx expression was analyzed by Western blotting. L-actin was used as an internal control. B: The signal inten-
sities shown in A were quanti¢ed with NIH image analysis software. Data are expressed relative to the intensity of L-actin (lane 1). The open
and closed bars indicate relative intensities of L-actin and HBx, respectively. C: Combination of 0.3 Wg of pNFUB-Luc and 50 ng of pRL-TK-
luc (lanes 1^5) or combination of 0.3 Wg of pLuc-MCS and 50 ng of pRL-TK-luc (lanes 6^8) were cotransfected with 0.3 Wg of pHLApr-1 con-
trol vehicle or 0.3 Wg of HBx expression vector into HuH-7. Twenty-four hours later, the cells were incubated with varying concentrations (0^
1000 IU/ml) of IFN-K for 24 h, then luciferase activity in the cells was analyzed as described in Section 2. Data are expressed as meanTS.D.
of ¢ve separate experiments. A representative HBx expression in each cell lysate is also shown at the bottom. D: 0.3 Wg of pNFUB-Luc and 50
ng of pRL-TK-luc were cotransfected with 0.3 Wg of pHLApr-1 control vehicle or 0.3 Wg of HBx expression vector into HuH-7. Twenty-four
hours later, the cells were incubated with 100 IU/ml of IFN-K for varying periods (2^48 h), then luciferase activity in the cells was analyzed.
E: 0.3 Wg of pNFUB-Luc and 50 ng of pRL-TK-luc were cotransfected with 0.3 Wg of pGEM11Zf[+] control vehicle or 0.3 Wg of full length
HBV DNA into HuH-7. Twenty-four hours later, the cells were incubated with varying concentrations (0^1000 IU/ml) of IFN-K for 24 h, then
luciferase activity in the cells was analyzed.
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in a dose-dependent manner (lanes 1^5), however, these
changes were not observed in the assay using pLuc-MCS re-
porter plasmid lacking the NF-UB binding site (lanes 6^8). In
addition, inhibitory e¡ect of IFN-K on the HBx-mediated
NF-UB activation became obvious in parallel with the incu-
bation periods (Fig. 3D). Western blot analysis showed that
the IFN-K had no e¡ect on the HBx expression in HuH-7 cells
(Fig. 3A^C). Therefore, it is likely that IFN-K could block the
NF-UB activating pathway triggered by HBx. Similarly, IFN-
K also dose dependently repressed the NF-UB activation in-
duced by full length HBV DNA transfection (Fig. 3E). How-
ever, in contrast to IFN-K, IFN-Q only slightly suppressed the
HBx-mediated NF-UB activation even in the higher concen-
trations or longer incubation periods (Fig. 4A,B).
4. Discussion
In the current study, the vector-based HBx expression acti-
vated transcriptional activity of NF-UB in HuH-7 cells in ac-
cordance with other in vitro studies [6^8]. In addition, trans-
fection of full length linear monometric HBV genome could
weakly but signi¢cantly activate NF-UB, which was probably
due to the very low level of HBx expression from full length
HBV genome (data not shown). Recently, Guo et al. [15]
reported that NF-UB was expressed di¡usely in HCC tissues
and its localization in the cells was closely related to the ex-
pression of HBx. They detected that NF-UB was expressed in
both the cytoplasm and nuclei of HCC cells in which HBx was
positive, whereas NF-UB was expressed only in the cytoplasm
of HCC cells in which HBx was negative. They further con-
¢rmed that HBx could stimulate the translocation of NF-UB
into nucleus in cultured HCC cells. These ¢ndings suggested
that activation of NF-UB is also linked to HBx in vivo.
However, how HBx stimulates NF-UB activity has yet to be
determined. HBx has been reported to activate NF-UB
through turning on the ras-raf-MAP kinase cascade [6,7]
and inducing the degradation of IUBK and NF-UB precur-
sor/inhibitor p105 [7]. Alternatively, HBx could directly inter-
act with IUBK and prevent its association with NF-UB and
induce its disassociation from NF-UB [8]. In this study, we
showed that HBx-mediated activation of NF-UB was re-
pressed by expression of dominant negative IKKK and
IUBK. These results are consistent with the recent report by
Kim et al. [26] that dominant negative NF-UB-inducing kinase
(NIK), IKK or IUB markedly attenuated the HBx-mediated
NF-UB activation, and that the target disruption of tumor
necrosis factor-K (TNF-K) receptor1 (TNFR1) gene com-
pletely abolished the HBx-mediated NF-UB activation. Taken
together, it is likely that TNFR1 and following NIK-IKK-IUB
signaling play essential roles in HBx-mediated NF-UB activa-
tion.
IFN-K are known to have antiproliferative e¡ects on hu-
man HCC cells, both in vivo and in vitro [27,28]. The e¡ec-
tiveness of IFN-K in treating HCC patients has been reported
positively in a few previous clinical trials [20,29]. It was also
shown that IFN delays or prevents HCC in patients with
HBV-related cirrhosis [19]. In addition, combination of
IFN-K and 5-FU signi¢cantly prolonged the survival rate of
patients with HCC [30]. These observations suggest that IFN-
K has a capability of anticancer agents against HCC although
its precise mechanisms are not fully understood. Recently, it
was reported that IFN-K suppressed the activation of NF-UB
composed of RelA-p50 and potentiated TNF-K-induced apo-
ptosis in Jurkat cells and human cervical cancer cells [31,32].
Similarly, Shigeno et al. [33] reported that IFN-K pretreat-
ment repressed the TNF-related apoptosis inducing ligand
(TRAIL)-mediated activation of NF-UB composed of RelA-
p50, and decreased its transcriptional activity in HuH-7 cells,
resulting in sensitizing these cells to TRAIL-induced apopto-
sis. Moreover, Wen et al. [34] recently reported that overex-
pression of p202, an IFN-K-inducible protein, was capable of
sensitizing breast cancer cells to TNF-K-mediated apoptosis
through the inactivation of NF-UB by its interaction with
p202. In the present study, IFN-K signi¢cantly inhibited the
HBx-mediated NF-UB activation in dose- and time-dependent
manner. Since HBx activates NF-UB signaling similar to
TNF-K [27], it is conceivable that IFN-K can inhibit HBx-
mediated NF-UB activation as well as TNF-K-mediated NF-
UB activation. Whereas, IFN-Q only weakly inhibited the
HBx-mediated NF-UB activation, suggesting that the IFN-K
speci¢c signaling molecules such as an IFN-stimulated gene
factor-3 may mediate an inhibitory e¡ect of IFN-K.
In conclusion, we have demonstrated that IFN-K could in-
hibit the HBx-mediated activation of NF-UB in human hep-
atoma cells. These results suggest that IFN-K may exhibit
Fig. 4. E¡ect of IFN-Q on the HBx-mediated NF-UB activation. 0.3
Wg of pNFUB-Luc and 50 ng of pRL-TK-luc were cotransfected
with 0.3 Wg of pHLApr-1 control vehicle or 0.3 Wg of HBx expres-
sion vector into HuH-7. Twenty-four hours later, the cells were in-
cubated with varying concentrations (0^1000 IU/ml) of IFN-Q for
24 h (A) or incubated with 100 IU/ml of IFN-Q for varying periods
(2^48 h) (B), then luciferase activity in the cells was analyzed as de-
scribed in Section 2. Data are expressed as meanTS.D. of ¢ve sepa-
rate experiments.
FEBS 27683 9-10-03
K. Ohata et al./FEBS Letters 553 (2003) 304^308 307
antitumor activity in HBV-related HCC through inhibiting
the NF-UB activation triggered by HBx.
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